Patents by Inventor Czeslaw Radziejewski
Czeslaw Radziejewski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7063840Abstract: The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.Type: GrantFiled: June 24, 2002Date of Patent: June 20, 2006Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, Joanne Bruno, Mitchell Goldfarb, Thomas H. Aldrich, Peter C. Maisonpierre, Czeslaw Radziejewski, Pamela F. Jones, George D. Yancopoulos
-
Publication number: 20040101920Abstract: Methods of utilizing a biosensor platform for the purpose of studying macromolecule interactions is provided. Also provided are methods of sorting monoclonal antibodies directed against a particular antigen into functional groups wherein each group exhibits a characteristic binding profile to the antigen.Type: ApplicationFiled: October 31, 2003Publication date: May 27, 2004Inventors: Czeslaw Radziejewski, Ergang Shi
-
Patent number: 6645484Abstract: The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.Type: GrantFiled: October 12, 2000Date of Patent: November 11, 2003Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, JoAnne Bruno, Mitchell Goldfarb, Thomas H. Aldrich, Peter C. Maisonpierre, Czeslaw Radziejewski, Pamela F. Jones, George D. Yancopoulos
-
Publication number: 20030166858Abstract: The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.Type: ApplicationFiled: June 24, 2002Publication date: September 4, 2003Inventors: Samuel Davis, Joanne Bruno, Mitchell Goldfarb, Thomas H. Aldrich, Peter C. Maisonpierre, Czeslaw Radziejewski, Pamela F. Jones, George D. Yancopoulos
-
Publication number: 20030166857Abstract: The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.Type: ApplicationFiled: June 24, 2002Publication date: September 4, 2003Inventors: Samuel Davis, Joanne Bruno, Mitchell Goldfarb, Thomas H. Aldrich, Peter C. Maisonpierre, Czeslaw Radziejewski, Pamela F. Jones, George D. Yancopoulos
-
Publication number: 20030109677Abstract: The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.Type: ApplicationFiled: December 17, 2002Publication date: June 12, 2003Inventors: Samuel Davis, JoAnne Bruno, Mitchell Goldfarb, Thomas H. Aldrich, Peter C. Maisonpierre, Czeslaw Radziejewski, Pamela F. Jones, George D. Yancopoulos
-
Publication number: 20020173627Abstract: The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.Type: ApplicationFiled: June 24, 2002Publication date: November 21, 2002Inventors: Samuel Davis, Joanne Bruno, Mitchell Goldfarb, Thomas H. Aldrich, Peter C. Maisonpierre, Czeslaw Radziejewski, Pamela F. Jones, George D. Yancopoulos
-
Patent number: 6433143Abstract: The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptor body, which specifically binds a human TIE-2 ligand. The invention also provides an antibody that specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.Type: GrantFiled: September 16, 1999Date of Patent: August 13, 2002Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, Joanne Bruno, Mitchell Goldfarb, Thomas H. Aldrich, Peter C. Maisonpierre, Czeslaw Radziejewski, Pamela F. Jones, George D. Yancopoulos
-
Patent number: 6166185Abstract: The present invention provides for an isolated nucleic acid molecule encoding a human TIE-2 ligand. In addition, the invention provides for a receptor body which specifically binds a human TIE-2 ligand. The invention also provides an antibody which specifically binds a human TIE-2 ligand. The invention further provides for an antagonist of human TIE-2. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE-2 receptor, a method of blocking the growth or differentiation of a cell expressing the TIE-2 receptor and a method of attenuating or preventing tumor growth in a human.Type: GrantFiled: September 28, 1998Date of Patent: December 26, 2000Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Samuel Davis, JoAnne Bruno, Mitchell Goldfarb, Thomas H. Aldrich, Peter C. Maisonpierre, Czeslaw Radziejewski, Pamela F. Jones, George D. Yancopoulos
-
Patent number: 6022694Abstract: The present invention provides for a screen for a polypeptide ligand that can bind to the Tyro-10 (DDR-2) or NEP (DDR-1) receptor and that can promote a differential function and/or influence the phenotype, such as growth and/or proliferation, of cells that bear the receptor. The present invention also provides a method of screening for a molecule capable of competing with collagen for binding to the extracellular domain of a Tyro-10 (DDR-2) or NEP (DDR-1) receptor comprising contacting a sample suspected of containing the molecule with the extracellular domain of a Tyro-10 (DDR-2) or NEP (DDR-1) receptor in the presence of collagen under conditions in which the collagen is capable of binding to the extracellular domain and detecting binding of the molecule to the Tyro-10 (DDR-2) or NEP (DDR-1) receptor extracellular domain. The invention further contemplates the utilization of collagen to support the growth, survival, or differentiation of Tyro-10 (DDR-2) or NEP (DDR-1) expressing cells.Type: GrantFiled: December 29, 1997Date of Patent: February 8, 2000Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Czeslaw Radziejewski, Ajay Shrivastava, George D. Yancopoulos